Amneal Pharmaceuticals announced it has received Abbreviated New Drug Application approval from the U.S. Food and Drug Administration for ciprofloxacin and dexamethasone otic suspension. This product is a combination of ciprofloxacin, a fluoroquinolone antibacterial and dexamethasone, a corticosteroid, and is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in Acute Otitis Externa in pediatric, adult, and elderly patients due to staphylococcus aureus and pseudomonas aeruginosa. “This approval represents the addition of another complex, high value medicine,” said Andy Boyer, Executive Vice President, Chief Commercial Officer – Generics. “It reflects the ongoing shift of our leading affordable medicines portfolio towards complex products and the continued successful diversification of our business.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals price target raised to $8 from $6 at Piper Sandler
- Amneal Pharma and the AI Dilemma: Balancing Innovation with Emerging Risks and Regulations
- Amneal Pharmaceuticals (NASDAQ:AMRX) Presents a Compelling Option for Value Investors
- Amneal Pharmaceuticals management to meet with Piper Sandler
- Options Volatility and Implied Earnings Moves Today, March 01, 2024